Cargando…

The prognostic value of p62 in solid tumor patients: a meta-analysis

p62, as a scaffolding/adaptor protein, is involved in multiple physiological processes include inflammation, autophagy and mitosis. However, the influence of p62 in cancer patients has not been comprehensively investigated. Moreover, the prognostic value of p62 for the survival of patients with soli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruan, Haihua, Xu, Jingyue, Wang, Lingling, Zhao, Zhenyu, Kong, Lingqin, Lan, Bei, Li, Xichuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790537/
https://www.ncbi.nlm.nih.gov/pubmed/29423120
http://dx.doi.org/10.18632/oncotarget.23101
_version_ 1783296465791090688
author Ruan, Haihua
Xu, Jingyue
Wang, Lingling
Zhao, Zhenyu
Kong, Lingqin
Lan, Bei
Li, Xichuan
author_facet Ruan, Haihua
Xu, Jingyue
Wang, Lingling
Zhao, Zhenyu
Kong, Lingqin
Lan, Bei
Li, Xichuan
author_sort Ruan, Haihua
collection PubMed
description p62, as a scaffolding/adaptor protein, is involved in multiple physiological processes include inflammation, autophagy and mitosis. However, the influence of p62 in cancer patients has not been comprehensively investigated. Moreover, the prognostic value of p62 for the survival of patients with solid tumors remains controversial. In this present meta-analysis, twenty suitable articles were identified from PubMed, EMBASE and Web of Science, Nature databases, including 4271 patients. A random-effect or fixed-effect model was adopted to correlate p62 expression with different outcome measured in entire tumors. Combined with results of hazard ratios (HRs) and 95% confidence intervals (CIs), we concluded that higher expression of p62 is associated with poorer overall survival (OS) (HR: 2.22, 95% CI: 1.82–2.71, P < 0.05), disease-free survival (DFS) (HR = 2.48, 95% CI: 1.78–3.46, P < 0.05) and even certain clinicopathological parameters, such as lymph node metastasis (RR = 1.21, 95% CI: 1.06–1.37) and clinical stages (RR = 1.27, 95% CI: 1.12–1.45), in cancer patients. Consequently, our data showed that p62 might be an effective poor prognostic factor for patients with various solid tumors.
format Online
Article
Text
id pubmed-5790537
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57905372018-02-08 The prognostic value of p62 in solid tumor patients: a meta-analysis Ruan, Haihua Xu, Jingyue Wang, Lingling Zhao, Zhenyu Kong, Lingqin Lan, Bei Li, Xichuan Oncotarget Meta-Analysis p62, as a scaffolding/adaptor protein, is involved in multiple physiological processes include inflammation, autophagy and mitosis. However, the influence of p62 in cancer patients has not been comprehensively investigated. Moreover, the prognostic value of p62 for the survival of patients with solid tumors remains controversial. In this present meta-analysis, twenty suitable articles were identified from PubMed, EMBASE and Web of Science, Nature databases, including 4271 patients. A random-effect or fixed-effect model was adopted to correlate p62 expression with different outcome measured in entire tumors. Combined with results of hazard ratios (HRs) and 95% confidence intervals (CIs), we concluded that higher expression of p62 is associated with poorer overall survival (OS) (HR: 2.22, 95% CI: 1.82–2.71, P < 0.05), disease-free survival (DFS) (HR = 2.48, 95% CI: 1.78–3.46, P < 0.05) and even certain clinicopathological parameters, such as lymph node metastasis (RR = 1.21, 95% CI: 1.06–1.37) and clinical stages (RR = 1.27, 95% CI: 1.12–1.45), in cancer patients. Consequently, our data showed that p62 might be an effective poor prognostic factor for patients with various solid tumors. Impact Journals LLC 2017-12-07 /pmc/articles/PMC5790537/ /pubmed/29423120 http://dx.doi.org/10.18632/oncotarget.23101 Text en Copyright: © 2018 Ruan et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Meta-Analysis
Ruan, Haihua
Xu, Jingyue
Wang, Lingling
Zhao, Zhenyu
Kong, Lingqin
Lan, Bei
Li, Xichuan
The prognostic value of p62 in solid tumor patients: a meta-analysis
title The prognostic value of p62 in solid tumor patients: a meta-analysis
title_full The prognostic value of p62 in solid tumor patients: a meta-analysis
title_fullStr The prognostic value of p62 in solid tumor patients: a meta-analysis
title_full_unstemmed The prognostic value of p62 in solid tumor patients: a meta-analysis
title_short The prognostic value of p62 in solid tumor patients: a meta-analysis
title_sort prognostic value of p62 in solid tumor patients: a meta-analysis
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790537/
https://www.ncbi.nlm.nih.gov/pubmed/29423120
http://dx.doi.org/10.18632/oncotarget.23101
work_keys_str_mv AT ruanhaihua theprognosticvalueofp62insolidtumorpatientsametaanalysis
AT xujingyue theprognosticvalueofp62insolidtumorpatientsametaanalysis
AT wanglingling theprognosticvalueofp62insolidtumorpatientsametaanalysis
AT zhaozhenyu theprognosticvalueofp62insolidtumorpatientsametaanalysis
AT konglingqin theprognosticvalueofp62insolidtumorpatientsametaanalysis
AT lanbei theprognosticvalueofp62insolidtumorpatientsametaanalysis
AT lixichuan theprognosticvalueofp62insolidtumorpatientsametaanalysis
AT ruanhaihua prognosticvalueofp62insolidtumorpatientsametaanalysis
AT xujingyue prognosticvalueofp62insolidtumorpatientsametaanalysis
AT wanglingling prognosticvalueofp62insolidtumorpatientsametaanalysis
AT zhaozhenyu prognosticvalueofp62insolidtumorpatientsametaanalysis
AT konglingqin prognosticvalueofp62insolidtumorpatientsametaanalysis
AT lanbei prognosticvalueofp62insolidtumorpatientsametaanalysis
AT lixichuan prognosticvalueofp62insolidtumorpatientsametaanalysis